Yazdan Yazdanpanah

Yazdan Yazdanpanah

Auto-generated profile, based on publicly available information

Yazdan Yazdanpanah

Inserm, Bichat, ANRS MIE-INSERM, Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FLFrancois-Xavier Lescure
Francois-Xavier Lescure
LBLila Bouadma
Lila Bouadma
DNDuc Nguyen
Duc Nguyen
MPMarion Parisey
Marion Parisey
PWPaul-Henri Wicky
Paul-Henri Wicky
YYYazdan Yazdanpanah
Yazdan Yazdanpanah

2 June 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EDEric D’ortenzio
Eric D’ortenzio
SMSophie Matheron
Sophie Matheron
XLXavier de Lamballerie
Xavier de Lamballerie
BHBruno Hubert
Bruno Hubert
GPGéraldine Piorkowski
Géraldine Piorkowski
ILIsabelle Leparc-Goffart
Isabelle Leparc-Goffart
Zika virus (ZIKV), an emerging flavivirus, generally causes mild infection in humans but is associated with severe neurologic complications and adverse fetal outcomes. ZIKV is transmitted to humans primarily by aedes mosquitoes. However, there is some evidence of sexual transmission.1,2 Two studies have shown the presence of infectious ZIKV in semen.3 A recent article described detection of ZIKV RNA in semen 62 days after the onset of illness, but infectious virus was not cultured.4

25 October 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
GVGuillaume Voiriot
Guillaume Voiriot
BVBenoit Visseaux
Benoit Visseaux
JCJohana Cohen
Johana Cohen
LNLiem Binh Luong Nguyen
Liem Binh Luong Nguyen
MNMathilde Neuville
Mathilde Neuville
jean-francois timsitjean-francois timsit
jean-francois timsit
Multiplex polymerase chain reaction (mPCR) enables recovery of viruses from airways of patients with community-acquired pneumonia (CAP), although their clinical impact remains uncertain. Among consecutive adult patients who had undergone a mPCR within 72 hours following their admission to one intensive care unit (ICU), we retrospectively included those with a final diagnosis of CAP. Four etiology groups were clustered: bacterial, viral, mixed (viral-bacterial) and no etiology. A composite criterion of complicated course (hospital death or mechanical ventilation > 7 days) was used. A subgroup analysis compared patients with bacterial and viral-bacterial CAP matched on the bacterial pathogens. Among 174 patients (132 men [76 %], age 63 [53–75] years, SAPSII 38 [27;55], median PSI score 106 [78;130]), bacterial, viral, mixed and no etiology groups gathered 46 (26 %), 53 (31 %), 45 (26 %) and 30 (17 %) patients, respectively. Virus-infected patients displayed a high creatine kinase serum level, a low platelet count, and a trend toward more frequent alveolar-interstitial infiltrates. A complicated course was more frequent in the mixed group (31/45, 69 %), as compared to bacterial (18/46, 39 %), viral (15/53, 28 %) and no etiology (12/30, 40 %) groups (p < 0.01). In multivariate analysis, the mixed (viral-bacterial) infection was independently associated with complicated course (reference: bacterial pneumonia; OR, 3.58; CI 95 %, 1.16–11; p = 0.03). The subgroup analysis of bacteria-matched patients confirmed these findings. Viral-bacterial coinfection during severe CAP in adults is associated with an impaired presentation and a complicated course.

1 May 2022 in Infectious Diseases Now
Verified
Journal Article
Open access
AMAnna Maisa
Anna Maisa
GSGuillaume Spaccaferri
Guillaume Spaccaferri
LFL. Fournier
L. Fournier
JSJustine Schaeffer
Justine Schaeffer
JDJ. Deniau
J. Deniau
YYY. Yazdanpanah
Y. Yazdanpanah
We aimed to investigate the first Omicron cases detected in France in order to assess case characteristics and provide supporting information on the possible impact of this variant on the healthcare system. A standardized questionnaire was used to collect information from confirmed and probable Omicron cases. Median age of 468 investigated cases was 35 years, 376 were symptomatic (89%); 64% were vaccinated with two doses and 7% had received three doses. Loss of smell and taste were reported by 8.3% and 9% of cases, respectively. Seven cases were hospitalized, three of those were unvaccinated (including two with reported precondition). No admissions to intensive care and no deaths were reported. Our results confirm a mild clinical presentation among the first Omicron cases detected in France and highlight the importance for the national COVID-19 surveillance system to quickly detect and adapt to the emergence of a new variant.

19 August 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NPNathan Peiffer-Smadja
Nathan Peiffer-Smadja
ABAntoine Bridier-Nahmias
Antoine Bridier-Nahmias
VFValentine Marie Ferré
Valentine Marie Ferré
CCCharlotte Charpentier
Charlotte Charpentier
MGMathilde Garé
Mathilde Garé
BVBenoit Visseaux
Benoit Visseaux
An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was administered at a single dose of 700 mg in a one-hour IV injection in a referral center for the management of COVID-19 in France. Patients were closely monitored clinically and virologically with nasopharyngeal RT-PCR and viral whole genome sequencing. Six patients were treated for a nosocomial SARS-CoV-2 infection, all males, with a median age of 65 years and multiple comorbidities. All patients were infected with a B.1.1.7 variant, which was the most frequent variant in France at the time, and no patients had E484 mutations at baseline. Bamlanivimab was infused in the six patients within 4 days of the COVID-19 diagnosis. Four patients had a favorable outcome, one died of complications unrelated to COVID-19 or bamlanivimab, and one kidney transplant patient treated with belatacept died from severe COVID-19 more than 40 days after bamlanivimab administration. Virologically, four patients cleared nasopharyngeal viral shedding within one month after infusion, while two presented prolonged viral excretion for more than 40 days. The emergence of E484K mutants was observed in five out of six patients, and the last patient presented a Q496R mutation potentially associated with resistance. CONCLUSIONS: These results show a high risk of emergence of resistance mutants in COVID-19 patients treated with monoclonal antibody monotherapy.

10 November 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
YYYazdan Yazdanpanah
Yazdan Yazdanpanah
FGFrench COVID cohort investigators and study group
French COVID cohort investigators and study group